MedTrace Logo

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

NCT02440126 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 196

Last updated 2021-02-21

No results posted yet for this study

Summary

The purpose of the study is to develop an improved understanding of the long term pharmacokinetics and pharmacodynamics of natalizumab with both standard dosing and extended dosing, and collect additional samples to explore cell-based biomarkers of natalizumab treatment and PML risk.

Conditions

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Rocky Mountain MS Research Group, LLC

    lead OTHER

Principal Investigators

  • John F Foley, MD · Rocky Mountain MS Research Group, LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-03-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440126 on ClinicalTrials.gov